Cost of antipsychotic polypharmacy in the treatment of schizophrenia

BMC Psychiatry

Table 2 Total days on index drugs and concomitant antipsychotics.

Concurrent drug class with index drug	OLZ (N = 405)	RIS (N = 276)	QUE (N = 115)	p-value** (OLZ vs QUE)	p-value** (OLZ vs RIS)	p-value** (RIS vs QUE)
Total days on index drug post 1 year after initiation	280	260	239	0.0028	0.0435	0.0557
First episode of continuously on index drug	272	250	225	0.0023	0.0908	0.0162
Total concurrent days on other antipsychotics*
on other atypicals	36.1	49.4	110.6	< 0.0001	0.0742	0.0001
on typicals	105.1	79.3	69.4	0.0107	0.0119	0.4723
on all anti-psychotics	136.6	120.3	160.2	0.1106	0.1378	0.0109
Percent of patients with >= 30 days of concurrent use
on other atypicals	18.5%	25.4%	52.2%	< 0.0001	0.0322	< 0.0001
on typicals	48.2%	38.4%	33.0%	0.0041	0.0120	0.3171
on all anti-psychotics	61.7%	55.1%	72.2%	0.0396	0.0831	0.0017

* Total concurrent days of other antipsychotics while on the first episode of the index drug.
** Adjusted with comorbidity, age, race, gender, hospitalization status at initiation, schizoaffective diagnosis and insurance, site, time to initiation.

ISSN: 1471-244X